Last reviewed · How we verify
20-valent pneumococcal conjugate vaccine (20vPnC) (20-valent-pneumococcal-conjugate-vaccine-20vpnc)
20-valent pneumococcal conjugate vaccine (20vPnC) (generic name: 20-valent-pneumococcal-conjugate-vaccine-20vpnc) is a Vaccine drug developed by Pfizer Inc.. It is currently FDA-approved.
At a glance
| Generic name | 20-valent-pneumococcal-conjugate-vaccine-20vpnc |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Vaccine |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A PHASE 3, RANDOMIZED, PARTIALLY DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY TODDLERS 12 THROUGH 23 MONTHS OF AGE WITH 2 PRIOR I (Phase 3)
- A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION (Phase 3)
- A Phase 1, Randomized, Double-Blind, Third-Party-Unblinded Trial to Evaluate the Safety and Immunogenicity of 20-valent Pneumococcal Conjugate Vaccine (20vPnC) and 13-valent Pneumococcal Conjugate Vac (Phase 1)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, THIRD-PARTY-UNBLINDED TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 60 YEARS O (Phase 3)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (20VPNC) WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCI (Phase 3)
- A Phase 2, Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Infants (Phase 2)
- A Phase 1/2, Randomized, Double-Blind Trial of the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 18 Years of Age and Older (Phase 1)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN IN A SERIES OF 3 INFANT DOSES AND 1 TODDLER DOSE IN INFANTS IN I (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 20-valent pneumococcal conjugate vaccine (20vPnC) CI brief — competitive landscape report
- 20-valent pneumococcal conjugate vaccine (20vPnC) updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about 20-valent pneumococcal conjugate vaccine (20vPnC)
What is 20-valent pneumococcal conjugate vaccine (20vPnC)?
20-valent pneumococcal conjugate vaccine (20vPnC) (20-valent-pneumococcal-conjugate-vaccine-20vpnc) is a Vaccine drug developed by Pfizer Inc..
Who makes 20-valent pneumococcal conjugate vaccine (20vPnC)?
20-valent pneumococcal conjugate vaccine (20vPnC) is developed and marketed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).
What is the generic name of 20-valent pneumococcal conjugate vaccine (20vPnC)?
20-valent-pneumococcal-conjugate-vaccine-20vpnc is the generic (nonproprietary) name of 20-valent pneumococcal conjugate vaccine (20vPnC).
What development phase is 20-valent pneumococcal conjugate vaccine (20vPnC) in?
20-valent pneumococcal conjugate vaccine (20vPnC) is FDA-approved (marketed).
Related
- Manufacturer: Pfizer Inc. — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Compare: 20-valent pneumococcal conjugate vaccine (20vPnC) vs similar drugs
- Pricing: 20-valent pneumococcal conjugate vaccine (20vPnC) cost, discount & access